Comparison of immunogenicity of simultaneous and nonsimultaneous vaccination with MMR and JE vaccine among 15-month-old children - PubMed (original) (raw)
Clinical Trial
. 1999 May-Jun;40(3):161-5.
Affiliations
- PMID: 10910607
Clinical Trial
Comparison of immunogenicity of simultaneous and nonsimultaneous vaccination with MMR and JE vaccine among 15-month-old children
C Y Tseng et al. Acta Paediatr Taiwan. 1999 May-Jun.
Abstract
To evaluate the immunogenicity of measles- mumps- rubella (MMR) vaccination with Japanese encephalitis (JE) vaccine nonsimultaneously and simultaneously, 145 babies, aged 15 months were enrolled into two groups. Group A received MMR and JE vaccines nonsimultaneously at an interval of 6 weeks; group B received the vaccinations simultaneously. Antibody titers of MMR and JE were detected before and 8 weeks after vaccination. A total of 118 babies (61 in group A; 57 in group B) completed the study. In group A, mean increments of logarithmic geometric mean titers (GMTs) of MMR and JE were 4.51, 5.93, 4.07 and 1.99; seroresponse rates were 100% (61/61), 77.05% (47/61), 96.72% (59/61) and 59.02% (36/61) respectively. In group B, mean increments of logarithmic GMTs of MMR and JE were 4.35, 5.37, 4.44 and 1.93; seroresponse rates were 98.25% (56/57), 77.19% (44/57), 98.25% (56/57) and 57.89% (33/57) respectively. There were no significant differences between these two groups. These results suggest that simultaneous and nonsimultaneous vaccination with MMR and JE vaccines were similar in immunogenicity.
Similar articles
- Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Watson BM, et al. J Infect Dis. 1996 Mar;173(3):731-4. doi: 10.1093/infdis/173.3.731. J Infect Dis. 1996. PMID: 8627041 Clinical Trial. - A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
Gatchalian S, Cordero-Yap L, Lu-Fong M, Soriano R, Ludan A, Chitour K, Bock HL. Gatchalian S, et al. Southeast Asian J Trop Med Public Health. 1999 Sep;30(3):511-7. Southeast Asian J Trop Med Public Health. 1999. PMID: 10774661 Clinical Trial. - Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Usonis V, et al. Pediatr Infect Dis J. 1999 Jan;18(1):42-8. doi: 10.1097/00006454-199901000-00011. Pediatr Infect Dis J. 1999. PMID: 9951979 Clinical Trial. - [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine].
Takayama N, Kidokoro M, Suzuki K, Morita M. Takayama N, et al. Kansenshogaku Zasshi. 1992 Jun;66(6):776-80. doi: 10.11150/kansenshogakuzasshi1970.66.776. Kansenshogaku Zasshi. 1992. PMID: 1331262 Japanese. - [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
Trier H, Rønne T. Trier H, et al. Ugeskr Laeger. 1992 Jul 13;154(29):2008-13. Ugeskr Laeger. 1992. PMID: 1509566 Review. Danish.
Cited by
- Vaccines for preventing Japanese encephalitis.
Schiøler KL, Samuel M, Wai KL. Schiøler KL, et al. Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD004263. doi: 10.1002/14651858.CD004263.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636750 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources